dibekacin and Endocarditis

dibekacin has been researched along with Endocarditis* in 1 studies

Other Studies

1 other study(ies) available for dibekacin and Endocarditis

Article	Year
Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA. The Japanese journal of antibiotics, 2011, Volume: 64, Issue:6 Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin. Topics: Adult; Anti-Bacterial Agents; Dibekacin; Drug Monitoring; Drug Therapy, Combination; Endocarditis; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Treatment Outcome; Vancomycin	2011

Article

Year

Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA.

The Japanese journal of antibiotics, 2011, Volume: 64, Issue:6

Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

Topics: Adult; Anti-Bacterial Agents; Dibekacin; Drug Monitoring; Drug Therapy, Combination; Endocarditis; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Treatment Outcome; Vancomycin

2011